Clinical Trial Update: Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy With or Without Immunotherapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating immune PET imaging and proteomics to assess response to spatially fractionated or palliative radiotherapy with or without immu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Clear Cell Renal Cell Carcinoma
• Endometrial Cancer
• Malignant Melanoma
• Triple-negative Breast Cancer

Snippet

Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology | Conditions: Triple Negative Breast Cancer, Uterine Cervical Cancer | Phase 2 | Status: NOT_YET_RECRUITING